"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead


Call for Submissions: The Clinical & Public Health Implications of Abortion Bans & Restrictions

The Supreme Court’s decision to overturn Roe v. Wade has major national public health repercussions. While abortion has long been a hot topic in the political arena, we believe it should be viewed through a clinical and public health lens, not via one’s political ideology. Cureus is calling for submissions that relate to or address the clinical and public health implications of abortion bans and restrictions. We hope this initiative will help raise awareness and prompt discussion about abortion, reproductive rights and maternal mortality. While the United Stated Supreme Court decision to overturn Roe v. Wade prompted this call for articles, we understand that abortion access and reproductive rights are a global topic affecting people all over the world. Editors will consider original articles, review articles, editorials, case reports, and “autobiographical case reports.” Please add the keyword “abortion” to your submission to be included in the email campaign and newsroom page.  The deadline for submissions is October 31st, 2022. Example topics: Policy Surveillance for a Global Analysis of National Abortion Laws How Caring for Patients Could Change in a Post–Roe v. Wade US Experiences of Midwives and Nurses When Implementing Abortion Policies: A Systematic Integrative Review Navigating Loss of Abortion Services — A Large Academic Medical Center Prepares for the Overturn of Roe v. Wade Abortion: Access and Safety Worldwide

Jun 28, 2022

Call for Submissions: Psychoactive Drug Therapy

Deadline Extension: June 30th, 2022 Cureus is calling for submissions related to psychoactive therapeutic drug treatments. Relevant original articles, case reports, review articles, and technical reports will be featured on a devoted Therapeutic Psychoactive Drug Treatments page and email campaign. Examples of psychoactive drugs include (but are not limited to) psilocybin, MDMA, LSD, DMT, and cannabinoids. Once thought to be a dangerous and taboo part of counterculture, psychoactive drugs are gaining mainstream acceptance in the medical community. Several states and cities in the United States and countries around the world are beginning to legalize or decriminalize psilocybin and other psychoactive drugs for therapeutic or medicinal purposes. (1) Respected institutions such as Johns Hopkins University, the University of California, and the Icahn School of Medicine have opened centers to study psychedelics from a clinical perspective. (2) Several studies suggest these drugs can be safely administered and may have benefits for people with clinical depression and other psychological diagnoses, such as PTSD and anxiety. (3) Add the keyword “Psychoactive Drug” to your submission to be included in the email campaign and newsroom page. The deadline for submissions is June 30th, 2022. Cureus will accept submissions from all specialties. Example topics include: How ecstasy and psilocybin are shaking up psychiatry Psychedelic-assisted psychotherapy: a paradigm shift Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders Neuroscience of psychoactive substance use and dependence Psychedelics in palliative care

May 03, 2022

Video Abstract Submissions

  Submit a Video Abstract Summary Cureus is dedicated to helping authors promote their research within the medical community. Short videos describing your article and findings build buzz and spread awareness of your research.  Submit a 30-second to two-minute “self-portait-style” video summary of your Cureus article and we’ll share your video with over 50,000 people across our Facebook, YouTube, Twitter, LinkedIn, and Instagram accounts. *You do not need your own social media accounts to participate. *Medical students should clearly state the name of the submitting author who oversaw the research. You can see examples of video abstract summaries here and here! Where to start? Record a short video (no more than two minutes) on your computer or phone that provides insight into your published Cureus article. What to include: Introduce yourself (your name and institution). You may have more than one author present in the video so feel free to include your co-authors. What was the conclusion of your research? Why is this topic of interest to the general public or the medical community? What will you do next? Will you expand on this research? Are you starting new research?  What to be aware of: Please stay on topic and stick to the subject matter of the article. Make sure there is ample lighting. Find a quiet place to film, free of any background noise and distractions. We recommend adding subtitles to your video but this is not required. We suggest the website: https://www.veed.io/  You can email your video to [email protected] Please include any social media handles for you, your co-authors, and your institution so we can tag everyone properly. Don't forget to subscribe to our YouTube Channel!

Apr 25, 2022

Presentation Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions

Sponsored by IRRAS Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions The neurosurgery team from the Rockefeller Neuroscience Institute at West Virginia University and WVU Medicine Ruby Memorial Hospital (WVUH), led by Dr. Nicholas Brandmeir, presented the clinical outcomes from the first 45 patients they treated with the new breakthrough technology, IRRAflow, a dynamic system that provides a therapeutic approach to treating intracranial bleeding. The data presented confirms the preliminary effectiveness of the IRRAflow system’s automated irrigation by showing a 0% occlusion rate during the entire course of treatment. On the other hand, clinical literature documents that traditional passive drainage solutions have catheter occlusion rates of up to 47%.1                                     Additionally, IRRAflow’s mechanism of action was also shown to more effectively remove collected blood after intracranial bleeding. The average treatment time with IRRAflow was 6.8 days, and only 13% of patients required the placement of a shunt after IRRAflow treatment. This percentage of shunt dependence with IRRAflow compares favorably to data from the CLEAR-III where 18% of patients required shunt placement after treatment with a passive ventricular drain.  Click the image above to view the PDF and learn about how preliminary data confirms that IRRAflow might reduce rates of catheter occlusion, infections, symptomatic and radiographic vasospasm.                                      1. Fargen KM, Hoh BL, Neal D, O’Connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. Journal of Neurosurgery. 2015:1-8.

Mar 29, 2022